尚荣医疗(002551) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥309,400,196.89, a decrease of 36.08% compared to ¥484,056,837.33 in the same period last year[3] - Net profit attributable to shareholders was ¥7,031,710.72, down 32.73% from ¥10,452,588.72 year-on-year[3] - Basic and diluted earnings per share were both ¥0.008, representing a decrease of 33.33% from ¥0.012 in the same period last year[3] - Total operating revenue for Q1 2023 was CNY 309.40 million, a decrease of 36.1% compared to CNY 484.06 million in the same period last year[23] - Net profit for Q1 2023 was CNY 7.76 million, a decline of 41.5% compared to CNY 13.24 million in Q1 2022[23] - The company recorded a comprehensive income total of CNY -3.32 million for Q1 2023, compared to CNY 14.18 million in the same period last year[23] Cash Flow - The net cash flow from operating activities was -¥30,079,313.39, a decline of 260.79% compared to ¥18,707,357.26 in the previous year[3] - Operating cash inflow totaled ¥290,425,878.68, down 19.4% from ¥360,559,289.98 in the previous period[25] - Cash inflow from investment activities reached ¥356,502,627.92, an increase of 6.5% from ¥334,367,863.67[25] - Net cash flow from investment activities was ¥64,062,883.84, up 43.3% from ¥44,727,900.04 in the previous period[25] - Cash inflow from financing activities was ¥187,390.40, significantly down from ¥30,813,168.68 in the previous period[25] - Net cash flow from financing activities was -¥7,253,996.41, an improvement from -¥8,975,815.59 in the previous period[25] - The ending balance of cash and cash equivalents was ¥695,928,506.41, slightly down from ¥704,018,477.93 in the previous period[25] - Total cash and cash equivalents increased by ¥43,288,502.68 during the period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,186,194,790.92, down 1.74% from ¥4,260,470,294.03 at the end of the previous year[3] - The total liabilities amounted to CNY 1,220.29 million, a slight decrease from CNY 1,261.19 million year-over-year[21] - The total amount involved in the arbitration application with Xuchang Second People's Hospital is RMB 63,686,100.00, excluding legal and arbitration fees[12] - The assessed value of the liquidated assets is RMB 117,751,800.00[11] Shareholder Information - The total number of common shareholders at the end of the reporting period is 79,173[8] - The largest shareholder, Liang Guiqiu, holds 29.55% of the shares, totaling 249,586,723 shares[8] - The company has a total of 62,396,681 unrestricted shares held by the largest shareholder, Liang Guiqiu[8] - The company has a total of 1,848,900 shares held by shareholder Guo Qin through a credit securities account[8] - The company has a total of 2,497,286 shares held by shareholder Jin Yude through a credit securities account[8] Contracts and Projects - The company has significant ongoing contracts, including a project with a contract value of 60,000,000 RMB for the Shaanxi Province Chengcheng County Hospital, currently in the completion acceptance stage[10] - The company is involved in a project with a contract value of 15,000,000 RMB for the Henan Province Ningling County People's Hospital, also in the completion acceptance stage[10] - The company is currently working on the Fuzhou City Health Bureau project with a contract value of 23,994,592 RMB, with two health centers already completed[10] - The company has a total of 40,000,000 RMB in contracts for the Jiangxi Province Nanfeng County Hospital project, which is in the completion acceptance stage[10] - The company has a total of 37,611,199 RMB in contracts for the Guangdong Province Heshan City People's Hospital project, which is currently under construction[10] Research and Development - Research and development expenses decreased by 70.60%, amounting to a reduction of ¥5,216,801.30 due to fewer R&D projects[6] - Research and development expenses for Q1 2023 were CNY 2.17 million, significantly lower than CNY 7.39 million in Q1 2022, indicating a reduction in R&D investment[23] Legal Matters - The arbitration amount involving Xuchang Second People's Hospital is RMB 293,182,800.00, which includes project payments, interest, penalties, and legal fees[12] - The company received a civil ruling from the Henan Intermediate People's Court, which stated that the facts and evidence regarding the bankruptcy of Xuchang Second People's Hospital were insufficient[15] - The company will closely monitor the restructuring progress of Xuchang Second People's Hospital and fulfill its information disclosure obligations[15] Future Outlook - Future outlook and strategic initiatives were not explicitly mentioned in the provided content, indicating a potential area for further inquiry in upcoming reports[24] - The company plans to invest the proceeds from the sale of its subsidiary in the medical equipment industry in Fuping County[16] Audit Status - The company’s first quarter report was not audited[27]